Poly Group Partners for New Antimicrobial Material Options

WEST LAFAYETTE, Ind. – Royer Corp. and Poly Group LLC finalized an exclusive partnership June 22 that results in the manufacture of antimicrobial custom plastic injection molded parts in Madison, Indiana.

Nouvex antimicrobial technology was discovered at Purdue University by a group led by Jeffrey Youngblood, a professor in Purdue’s School of Materials Engineering.  Poly Group LLC holds an exclusive, worldwide license to the IP covering Nouvex, which includes a granted U.S. patent.

“It is rewarding to see our technology go to the market and help make a difference, particularly during this worldwide pandemic,” Youngblood said.

Royer Corp., a Madison-based manufacturer, serves a variety of industries that will benefit from an antimicrobial option – especially given the new safety challenges businesses are facing because of the COVID-19 pandemic.

Royer will infuse Nouvex material in a variety of custom injection molded applications such as airline and mass transit interior parts, food service and hospitality components/disposables, cosmetic applicators, housewares and commercial product pieces.

“Given our company’s unique injection molding capabilities, virtually any custom plastic product can be made in antimicrobial material,” said Roger Williams, CEO of Royer.

The antimicrobial technology marketed as Nouvex has been licensed exclusively and globally to Poly Group by the Purdue Research Foundation Office of Technology Commercialization.

The office is now housed in the Convergence Center for Innovation and Collaboration in Discovery Park District, adjacent to the Purdue campus.

About Poly Group LLC

Poly Group LLC is located in the Purdue Research Park in New Albany, Indiana. The antimicrobial technology marketed as Nouvex has been licensed exclusively and globally to Poly Group by the Purdue Research Foundation Office of Technology Commercialization. Poly Group has successfully registered Nouvex with the U.S. Environmental Protection Agency (EPA), as a material preservative; EPA Reg. No. 91413-2.

About Purdue Research Foundation Office of Technology Commercialization

The Purdue Research Foundation Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university’s academic activities through commercializing, licensing and protecting Purdue intellectual property. The office recently moved into the Convergence Center for Innovation and Collaboration in Discovery Park District, adjacent to the Purdue campus. In fiscal year 2019, the office reported 136 deals finalized with 231 technologies signed, 380 disclosures received and 141 issued U.S. patents. The office is managed by the Purdue Research Foundation, which received the 2019 Innovation and Economic Prosperity Universities Award for Place from the Association of Public and Land-grant Universities. In 2020, IPWatchdog Institute ranked Purdue third nationally in startup creation and in the top 20 for patents. The Purdue Research Foundation is a private, nonprofit foundation created to advance the mission of Purdue University.

Contact Poly Group LLC

For more information on the science behind Nouvex and ways you can help bring this solution to market faster, contact Craig Kalmer, Chief Operating Officer, Poly Group LLC at (812) 590-4750.

Image Credit

Cover image courtesy of Royer Corporation.

Solving Pandemic Challenges

A Purdue-licensed discovery is now available to a world that so desperately needs its protecting power. Indiana-company and global licensee Poly Group LLC has branded its innovative product as Nouvex™. Put simply, Nouvex is a polymeric family of materials that protects surfaces and is scientifically proven to have antimicrobial, antiviral, and antifungal effects, while also eradicating biofilms. Currently being tested against COVID-19, Nouvex formulations are already being integrated into plastics, resins, rubber, and latex and soon will be available in sanitizing sprays and wipes, powder coatings, paints, coatings, and wax, as well as woven and non-woven textiles.

What is Nouvex?

Nouvex combines a bio-compatible monomer with an antimicrobial monomer in formulations that are known to be both safe and effective, demonstrating low toxicity and significant biocompatability. Combined with its persistent effectiveness, Nouvex can be applied or integrated into various platforms and has staying power. That persistency reduces the number of applications needed to maintain a constant level of protection.

Nouvex is already an EPA-registered (91413-2) antimicrobial preservative. Poly Group hopes to fast-track additional testing, ultimately leading to additional EPA-approved health claims for both Nouvex and the products that utilize this technology. The company continues to build joint development agreements with companies interested in integrating Nouvex into their already-existing manufacturing processes and sanitization plans.

For more information on the science behind Nouvex and ways you can help bring this solution to market faster, contact Craig Kalmer, Chief Operating Officer, Poly Group LLC at (812) 590-4750.

Photo by Kai Dahms on Unsplash

Healthcare Associated Infections Focus

Petri dish with bacterial colonies

1 in 31 hospital patients has at least one healthcare-associated infection (HAI) on any given day. The 2018 National and State HAI Progress Report provides data on central line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), ventilator-associated events (VAEs), surgical site infections (SSIs), methicillin-resistant Staphylococcus aureus (MRSA) bloodstream events, and Clostridioides difficile (C. difficile) events, formerly known as Clostridium difficile.

Ventilator-Associated Events

Ventilator-associated events are tracked nationally based on data collected from Acute Care Hospitals (ACHs) and Long-Term Acute Care Hospitals (LTACHs). Between 2017 and 2018, there wasn’t any statistically significant change in these reported events. Among these events, ventilator-associated pneumonia (VAP) is the most serious and controversial of the infections of critically ill patients. (1)

Ventilator-associated pneumonia is defined as pneumonia that occurs 48-72 hours or thereafter following endotracheal intubation, characterized by the presence of a new or progressive infiltrate, signs of systemic infection (fever, altered white blood cell count), changes in sputum characteristics, and detection of a causative agent VAP contributes to approximately half of all cases of hospital-acquired pneumonia VAP is estimated to occur in 9-27 % of all mechanically ventilated patients, with the highest risk being early in the course of hospitalization. It is the second most common nosocomial infection in the intensive care unit (ICU) and the most common in mechanically ventilated patients. The complex interplay between the endotracheal tube, presence of risk factors, and the virulence of the invading bacteria and host immunity largely determine the development of VAP. (2)

The American Thoracic Society, in conjunction with the Infectious Disease Society of America, published a guideline for the management of this particular healthcare-acquired infection. This evidence-based guideline outlines early and appropriate treatment with antibiotics. They also stress avoiding excessive antibiotics and ramping down antibiotic therapy based on microbiological cultures. (3)

Catheter-Associated Urinary Tract Infections

According to the CDC, when a urinary catheter is not put in correctly, not kept clean, or left in a patient for too long, germs can travel through the catheter and infect the bladder and kidneys. This type of healthcare-associated infection (HAI) is called catheter-associated urinary tract infection (CAUTI). This type of infection causes the “revolving door” of hospital re-admissions that costs the health care system nearly $4 billion dollars annually. This leads to antibiotic use which in turn leads to colonization of multi-drug resistant organisms. (4)

Educating facility staff (5) was key to reducing infection rates by about 40%. (6) This, in turn, caused a reduction in the frequency of lab tests being ordered. Too much testing can lead to false-positive results and the use of unnecessary antibiotics, which can encourage drug-resistant superbugs to evolve and spread.

As long-term care facilities implemented practices to reduce infection, the rate dropped from 6.4 infections per 1,000 catheter-days to 3.33. This can help reduce health care costs across the board. The US Department of Veterans Affairs and others funded an online calculator to estimate the costs of CAUTIs.

In Conclusion

Healthcare-associated infections are a serious healthcare issue. If you are a medical device manufacturer or durable medical equipment manufacturer that would like to incorporate an antimicrobial into your polymer, we urge you to Contact Us to discuss this data in further detail. If you would like to stay up to date about PolyGroup and Nouvex Antimicrobial, please subscribe to our newsletter.